复方甘草酸苷联合左西替利嗪治疗慢性荨麻疹有效性和安全性的Meta分析  

Efficacy and safety of Compound Glycyrrhizin combined with Levocetirizine in the treatment of chronic urticaria:a Meta-analysis

作　　者：郑子恢[1] 张碧华[1] 李琼[1] 王洋[1] 张白歌 马琳[1] 李文英[1] 金鹏飞[1] ZHENG Zi-hui;ZHANG Bi-hua;LI Qiong;WANG Yang;ZHANG Bai-ge;MA Lin;LI Wen-ying;JIN Peng-fei(Department of Pharmacy,Beijing Hospital,National Center of Gerontology,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital),Beijing 100730,China)

机构地区：[1]北京医院药学部国家老年医学中心中国医学科学院老年医学研究院北京市药物临床风险与个体化应用评价重点实验室(北京医院),北京100730

出　　处：《临床药物治疗杂志》2022年第2期60-66,共7页Clinical Medication Journal

基　　金：国家自然科学基金项目(81303216)。

摘　　要：目的系统评价复方甘草酸苷联合左西替利嗪治疗慢性荨麻疹的有效性和安全性。方法计算机检索PubMed、Cochrane Library、Embase、中国知网、万方数据库,检索时间从建库到2022年1月31日,中文数据库检索中国科技论文统计源期刊发表的复方甘草酸苷联合左西替利嗪治疗慢性荨麻疹的随机对照试验(RCT),英文数据库不做期刊限制。由2名研究者提取资料、选取文献、并评价纳入文章的偏倚风险后,采用RevMan 5.4进行Meta分析。结果共纳入8项RCT,包括918例患者,观察组474例,对照组444例。Meta分析结果显示,有效性方面,复方甘草酸苷联合左西替利嗪治疗慢性荨麻疹在总有效率(OR=6.14,95%CI:4.10~9.20,P<0.01)、痊愈率(OR=2.75,95%CI:2.04~3.72,P<0.01)、显效率(OR=1.58,95%CI:1.13~2.22,P<0.01)、复发率(OR=0.24,95%CI:0.11~0.52,P<0.01)、症状总积分(SMD=-2.17,95%CI:-3.76~-0.59,P<0.01)和皮肤病生活质量指数(MD=-1.92,95%CI:-3.76~-0.09,P<0.05)方面均优于对照组;不良反应方面,观察组(OR=0.56,95%CI:0.35~0.90,P<0.05)显著低于对照组,差异有统计学意义。结论现有证据表明,复方甘草酸苷联合左西替利嗪治疗慢性荨麻疹安全、有效,较单独使用左西替利嗪有明显优势。因纳入的RCT数量和质量所限,上述结论有待更多高质量RCT予以印证。Objective To systematically evaluate the efficacy and safety of Compound Glycyrrhizin with Levocetirizine in the chronic urticaria(CU).Methods PubMed,Cochrane Library,Embase,CNKI and Wanfang databases were searched from the establishment of the database to January 31,2022.Randomized controlled trials(RCTs)of Compound Glycyrrhizin combined with Levocetirizine in the treatment of CU published in Chinese journals were collected in the Chinese database,and journals were not in the English database.Two researchers extracted data,selected literatures,and evaluated the risk of bias in the included articles.Meta-analysis was performed using RevMan 5.4.Results A total of 8 RCTs were included in the analysis,involving 918 patients,474 in the experimental group and 444 in the control group.Results of the Meta-analysis showed that the total effective rate in the CU(OR=6.14,95%CI:4.10 to 9.20,P<0.01),cure rate(OR=2.75,95%CI:2.04 to 3.72,P<0.01),marked effective rate(OR=1.58,95%CI:1.13 to 2.22,P<0.01),recurrence rate(OR=0.24,95%CI:0.11 to 0.52,P<0.01),total symptom score(TSS)(SMD=-2.17,95%CI:-3.76 to-0.59,P<0.01)and dermatology life quality index(DLQI)(MD=-1.92,95%CI:-3.76 to-0.09,P<0.05)of the observation group were significantly better than the control group.In terms of adverse reactions,the observation group(OR=0.56,95%CI:0.35 to 0.90,P<0.05)was significantly lower than the control group.Conclusion The existing evidences suggest that Compound Glycyrrhizin with Levocetirizine is safer and more effective in the treatment of CU,compared to Levocetirizine alone.It is limited due to the quantity and quality of the included studies,and the above conclusions need to be verified by more high-quality RCTs.

关 键 词：复方甘草酸苷 左西替利嗪 慢性荨麻疹 META分析 随机对照试验 

分 类 号：R986[医药卫生—药品] R246.7[医药卫生—药学]